Vaccines and RNA and genomic-based therapies have gained a lot of attention recently due to COVID-19. Last year was a breakthrough for the technology with the approval of the first mRNA-based therapy. The Vaccine and RNA Therapeutics stream will explore the technical challenges facing the formulation, development, manufacturing, and supply of next-generation vaccines, mRNA vaccines, mRNA gene therapies, RNAi, gene therapies, and cell therapies. Experts from pharma, biotech, academia, and government labs will convene in Boston in person and virtually to deep dive into the challenges associated with successfully developing and delivering these next-generation therapeutics.


Conferences Include:

Keynote and Featured Presentations

Disruptive Technologies for Formulation, Manufacturing, and Delivery: Enabling Advancements for Biologics and Vaccines Products into the Future
Jeff Blue, Executive Director, Vaccine Drug Product Development, Merck & Co., Inc.


Microneedle Development and Manufacturing for the Vaccines
Philippe-Alexandre Gilbert, PhD, Senior Program Officer, Vaccine Development and Surveillance, Bill and Melinda Gates Foundation


Living in the World of RNA Therapeutics Enabled by Lipid Nanoparticles
Mano Manoharan, PhD, Distinguished Scientist & Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals


Optimizing Drug Product Presentation and Manufacturing Processes for Genomic Medicines
Sandeep Yadav, PhD, Senior Director, Drug Product Formulation & Fill & Finish, Drug Product Formulation & Process Development, Sangamo Therapeutics